Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

The companies plan to develop a broad NGS panel to analyze all known biomarkers for cancer drugs, including tumor mutation burden and microsatellite instability.

Only three out of 10 sequencing workflows detected all variants in a synthetic reference sample, according to a study presented at ACMG.

The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.

Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.

The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.

The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.

Pages